文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

国际软组织肉瘤联盟:横纹肌肉瘤数据的基线分析

The International Soft Tissue Sarcoma Consortium: The baseline analysis of rhabdomyosarcoma data.

作者信息

Bisogno Gianni, Sparber-Sauer Monika, Rodeberg David, Merks Johannes H M, Koscielniak Ewa, Wolden Suzanne L, De Salvo Gian Luca, Del Bianco Paola, Xue Wei, Ebinger Martin, Vokuhl Christian, Venkatramani Rajkumar, Volchenboum Samuel L, Furner Brian, Minard Colin Veronique, Hawkins Douglas S

机构信息

Department of Women's and Children's Health, University of Padua, Padua, Italy.

Pediatric Hematology Oncology Division, University Hospital of Padua, Padua, Italy.

出版信息

Cancer. 2025 Jul 15;131(14):e35974. doi: 10.1002/cncr.35974.


DOI:10.1002/cncr.35974
PMID:40632016
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12239856/
Abstract

BACKGROUND: The International Soft Tissue Sarcoma Consortium (INSTRuCT) was established in 2017 to enhance international collaboration. This study describes the characteristics of rhabdomyosarcoma (RMS) patients in the INSTRuCT database and examines differences across contributing groups. METHODS: INSTRuCT includes data Children's Oncology Group (COG), Cooperative Weichteilsarkom Studiengruppe (CWS), and European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) along with prior studies from Malignant Mesenchymal Tumour Committee (MMT) and Italian Soft Tissue Sarcoma Committee (STSC). Data standardization was supported by the University of Chicago's Pediatric Cancer Data Commons. Pseudonymized patient-level data from clinical trials were harmonized. Differences across groups were assessed using χ or Kruskal-Wallis tests. RESULTS: As of March 2025, INSTRuCT includes 6972 RMS patients from 16 trials (1990-2016). Embryonal RMS was the most common histology in all groups (range, 45.4%-62.2%). Alveolar RMS was less frequent in EpSSG (26.8%) although the rate of RMS fusion-positive was comparable across groups (74.6%-81.9%). COG and EpSSG had more T1 tumors, (53.2% and 51.4%) with COG reporting more tumors <5 cm (52%). Nodal involvement was least reported in MMT (15.4%). Metastatic patients were less represented in MMT (11%) and EpSSG (13.3%). Tumor site distribution varied: genitourinary nonbladder/prostate RMS was more common in COG, whereas head and neck nonparameningeal and orbital RMS were more represented in MMT and STSC. MMT had fewer completely resected tumors (8.9%). CONCLUSION: Differences among RMS study populations reflect evolving diagnostic criteria and treatment strategies that should be considered in future analyses. INSTRuCT offers a valuable international data set for RMS research.

摘要

背景:国际软组织肉瘤联盟(INSTRuCT)于2017年成立,以加强国际合作。本研究描述了INSTRuCT数据库中横纹肌肉瘤(RMS)患者的特征,并探讨了各参与组之间的差异。 方法:INSTRuCT纳入了儿童肿瘤协作组(COG)、软组织肉瘤合作研究组(CWS)和欧洲儿科软组织肉瘤研究组(EpSSG)的数据,以及恶性间叶肿瘤委员会(MMT)和意大利软组织肉瘤委员会(STSC)之前的研究数据。芝加哥大学儿科癌症数据共享中心支持数据标准化。对来自临床试验的匿名患者水平数据进行了整合。使用χ检验或Kruskal-Wallis检验评估组间差异。 结果:截至2025年3月,INSTRuCT包括来自16项试验(1990 - 2016年)的6972例RMS患者。胚胎型RMS是所有组中最常见的组织学类型(范围为45.4% - 62.2%)。在EpSSG中,肺泡型RMS较少见(26.8%),尽管各组中RMS融合阳性率相当(74.6% - 81.9%)。COG和EpSSG的T1期肿瘤较多(分别为53.2%和51.4%),COG报告的肿瘤<5 cm的比例更高(52%)。MMT报告的淋巴结受累最少(15.4%)。MMT和EpSSG中转移性患者的比例较低(分别为11%和13.3%)。肿瘤部位分布各不相同:泌尿生殖系统非膀胱/前列腺RMS在COG中更常见,而头颈部非脑膜和眼眶RMS在MMT和STSC中更常见。MMT中完全切除的肿瘤较少(8.9%)。 结论:RMS研究人群之间的差异反映了不断演变的诊断标准和治疗策略,在未来的分析中应予以考虑。INSTRuCT为RMS研究提供了一个有价值的国际数据集。

相似文献

[1]
The International Soft Tissue Sarcoma Consortium: The baseline analysis of rhabdomyosarcoma data.

Cancer. 2025-7-15

[2]
Treatment and outcome of patients with localized intrathoracic and chest wall rhabdomyosarcoma: a report of the Cooperative Weichteilsarkom Studiengruppe (CWS).

J Cancer Res Clin Oncol. 2018-2-20

[3]
Lymph Node Staging and Treatment in Pediatric Patients With Soft Tissue Sarcomas: A Consensus Opinion From the Children's Oncology Group, European paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.

Pediatr Blood Cancer. 2025-4

[4]
Regional lymph node invasion in pediatric non-rhabdomyosarcoma soft tissue sarcoma: an international cohort study from the International Soft Tissue Sarcoma Consortium.

EClinicalMedicine. 2025-8-7

[5]
Prevalence of locoregional and distant lymph node metastases in children and adolescents/young adults with soft tissue sarcomas: a Bayesian meta-analysis of proportions.

EClinicalMedicine. 2025-8-7

[6]
Are There Sex Differences in the Association of Alcohol Consumption With the Risk of Soft Tissue Sarcoma? A Nationwide Population-based Study in Korea.

Clin Orthop Relat Res. 2025-6-25

[7]
Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.

Pediatr Blood Cancer. 2021-4

[8]
What Are the Complications, Function, and Survival of Tumor-devitalized Autografts Used in Patients With Limb-sparing Surgery for Bone and Soft Tissue Tumors? A Japanese Musculoskeletal Oncology Group Multi-institutional Study.

Clin Orthop Relat Res. 2023-11-1

[9]
Lymph node metastases in paediatric and young adult patients with non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): Findings from Children's Oncology Group (COG) study ARST0332.

Eur J Cancer. 2023-2

[10]
Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma.

ESMO Open. 2025-2

本文引用的文献

[1]
Reappraisal of prognostic factors used in the European Pediatric Soft Tissue Sarcoma Study Group RMS 2005 study for localized rhabdomyosarcoma to optimize risk stratification and generate a prognostic nomogram.

Cancer. 2024-7-1

[2]
INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) consensus statement: Imaging recommendations for the management of rhabdomyosarcoma.

Eur J Radiol. 2023-9

[3]
Pediatric Patients with Stage IV Rhabdomyosarcoma Significantly Benefit from Long-Term Maintenance Therapy: Results of the CWS-IV 2002 and the CWS DOK IV 2004-Trials.

Cancers (Basel). 2023-3-30

[4]
Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study.

J Clin Oncol. 2023-5-1

[5]
Creating a data commons: The INternational Soft Tissue SaRcoma ConsorTium (INSTRuCT).

Pediatr Blood Cancer. 2022-11

[6]
Molecular testing of rhabdomyosarcoma in clinical trials to improve risk stratification and outcome: A consensus view from European paediatric Soft tissue sarcoma Study Group, Children's Oncology Group and Cooperative Weichteilsarkom-Studiengruppe.

Eur J Cancer. 2022-9

[7]
Metastatic Rhabdomyosarcoma: Results of the European Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study.

J Clin Oncol. 2022-11-10

[8]
Long-term results from the multicentric European randomized phase 3 trial CWS/RMS-96 for localized high-risk soft tissue sarcoma in children, adolescents, and young adults.

Pediatr Blood Cancer. 2022-9

[9]
Long-Term Clinical Outcome and Prognostic Factors of Children and Adolescents with Localized Rhabdomyosarcoma Treated on the CWS-2002P Protocol.

Cancers (Basel). 2022-2-11

[10]
Pathology of childhood rhabdomyosarcoma: A consensus opinion document from the Children's Oncology Group, European Paediatric Soft Tissue Sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.

Pediatr Blood Cancer. 2021-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索